Role of cognitive enhancement in schizophrenia

References

• Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, “just the facts” what we know in 2008. 2. Epidemiology and etiology. Schizophr Res. 2008;102(1–3):1–18.
   PubMed Web of Science ®Google Scholar
• Van Os J, Kenis G, Rutten BP. The environment and schizophrenia. Nature. 2010;468(7321):203–212.
   PubMed Web of Science ®Google Scholar
• Burns JK. Pathways from cannabis to psychosis: a review of the evidence. Front Psychiatry. 2013;4:128.
   PubMedGoogle Scholar
• van Os J. A salience dysregulation syndrome. Br J Psychiatry. 2009;194(2):101–103.
   PubMed Web of Science ®Google Scholar
• Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry. 2005;57(10):1117–1127.
   PubMed Web of Science ®Google Scholar
• Okochi T, Ikeda M, Kishi T, et al. Meta-analysis of association between genetic variants in COMT and schizophrenia: an update. Schizophr Res. 2009;110(1–3):140–148.
   PubMed Web of Science ®Google Scholar
• Merritt K, McGuire P, Egerton A. Relationship between glutamate dysfunction and symptoms and cognitive function in psychosis. Front Psychiatry. 2013;4:151.
   PubMedGoogle Scholar
• Kennedy JL, Altar CA, Taylor DL, Degitiar I, Hornberger JC. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol. 2014;29(2):63–76.
   PubMed Web of Science ®Google Scholar
• Morgan VA, Waterreus A, Jablensky A. People living with psychotic illness in 2010: the second Australian national survey of psychosis. Aust N Z J Psychiatry. 2012;46(8):735–752.
   PubMed Web of Science ®Google Scholar
• Cooper J, Mancuso SG, Borland R, Slade T, Galletly C, Castle D. Tobacco smoking among people living with a psychotic illness: the second Australian Survey of Psychosis. Aust N Z J Psychiatry. 2012;46(9):851–863.
   PubMed Web of Science ®Google Scholar
• Morgan VA, Waterreus A, Jablensky A, et al. People living with psychotic illness 2010: report on the second Australian national survey. Commonwealth of Australia; November 2011. Available from: https://www.health.gov.au/internet/main/publishing.nsf/Content/mental-pubs-p-psych10. Accessed February 13, 2014.
   Google Scholar
• Borras L, Mohr S, Boucherie M, Dupont-Willemin S, Ferrero F, Huguelet P. Patients with schizophrenia and their finances: how they spend their money. Soc Psychiatry Psychiatr Epidemiol. 2007;42(12):977–983.
   PubMed Web of Science ®Google Scholar
• Greve J, Nielsen LH. Useful beautiful minds – an analysis of the relationship between schizophrenia and employment. J Health Econ. 2013;32(6):1066–1076.
   PubMed Web of Science ®Google Scholar
• Waghorn G, Saha S, Harvey C, et al. ‘Earning and learning’ in those with psychotic disorders: the second Australian national survey of psychosis. Aust N Z J Psychiatry. 2012;46(8):774–785.
   PubMed Web of Science ®Google Scholar
• Bond GR, Drake RE. Making the case for IPS supported employment. Adm Policy Ment Health. 2014;41(1):69–73.
   PubMed Web of Science ®Google Scholar
• Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophr Bull. 2000;26(1):119–136.
   PubMed Web of Science ®Google Scholar
• Harvey PD, Cornblatt B. Pharmacological treatment of cognition in schizophrenia: an idea whose method has come. Am J Psychiatry. 2008;165(2):163–165.
   PubMed Web of Science ®Google Scholar
• Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165(2):203–213.
   PubMed Web of Science ®Google Scholar
• Kern, RS, Nuechterlein KH, Green MF, et al. The MATRICS consensus cognitive battery, part 2: co-norming and standardization. Am J Psychiatry. 2008;165(2):214–220.
   PubMed Web of Science ®Google Scholar
• Green MF, Schooler NR, Kern RS, et al. Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. Am J Psychiatry. 2011;168(4):400–407.
   PubMed Web of Science ®Google Scholar
• Saykin AJ, Shtasel DL, Gur RE, et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry. 1994;51(2):124–131.
   PubMed Web of Science ®Google Scholar
• Bilder RM, Goldman RS, Robinson D, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry. 2000;157(4):549–559.
   PubMed Web of Science ®Google Scholar
• Zanelli J, Reichenberg A, Morgan K, et al. Specific and generalized neuropsychological deficits: a comparison of patients with various first-episode psychosis presentations. Am J Psychiatry. 2010;167(1):78–85.
   PubMed Web of Science ®Google Scholar
• Lewandowski KE, Cohen BM, Ongur D. Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder. Psychol Med. 2011;41(2):225–241.
   PubMed Web of Science ®Google Scholar
• Sun D, Phillips L, Velakoulis D, et al. Progressive brain structural changes mapped as psychosis develops in ‘at risk’ individuals. Schizophr Res. 2009;108(1–3):85–92.
   PubMed Web of Science ®Google Scholar
• Siris SG. Depression in schizophrenia: perspective in the era of “atypical” antipsychotic agents. Am J Psychiatry. 2000;157(9):1379–1389.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA, USA: American Psychiatric Association; 2013.
   Google Scholar
• Varese F, Smeets F, Drukker M, et al. Childhood adversities increase the risk of psychosis: a meta-analysis of patient-control, prospective- and cross-sectional cohort studies. Schizophr Bull. 2012;38(4):661–671.
   PubMed Web of Science ®Google Scholar
• Honzel N, Justus T, Swick D. Posttraumatic stress disorder is associated with limited executive resources in a working memory task. Cogn Affect Behav Neurosci. October 29, 2013. [Epub ahead of print.]
   Web of Science ®Google Scholar
• Ogino S, Miyamoto S, Miyake N, Yamaguchi N. Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function. Psychiatry Clin Neurosci. 2014;68(1):37–49.
   PubMed Web of Science ®Google Scholar
• Moore E, Mancuso SG, Slade T, Galletly CA, Castle DJ. The impact of alcohol and illicit drugs on people with psychosis: The second Australian national survey on psychosis. Aust N Z J Psychiatry. 2012;46(9):864–878.
   PubMed Web of Science ®Google Scholar
• Kalucy MJ, Grunstein R, Lambert T, Glozier N. Obstructive sleep apnoea and schizophrenia – a research agenda. Sleep Med Rev. 2013;17(5):357–365.
   PubMed Web of Science ®Google Scholar
• Guo X, Zhang Z, Wei Q, Lv H, Wu R, Zhao J. The relationship between obesity and neurocognitive function in Chinese patients with schizophrenia. BMC Psychiatry. 2013;13:109.
   PubMed Web of Science ®Google Scholar
• Dragovic M, Waters FA, Jablensky A. Estimating premorbid intelligence in schizophrenia patients: demographically based approach. Aust N Z J Psychiatry. 2008;42(9):814–818.
   PubMed Web of Science ®Google Scholar
• Dash SK. Cognitive impairment and diabetes. Recent Pat Endocr Metab Immune Drug Discov. 2013;7(2):155–165.
   PubMedGoogle Scholar
• Foley DL, Mackinnon A, Morgan VA, et al. Predictors of type 2 diabetes in a nationally representative sample of adults with psychosis. World Psychiatry. In press 2014.
   Google Scholar
• Van Hooren S, Versmissen D, Janssen I, et al. Social cognition and neurocognition as independent domains in psychosis. Schizophr Res. 2008;103(1–3):257–265.
   PubMed Web of Science ®Google Scholar
• Stratta P, Bustini M, Daneluzzo E, Riccardi I, D’Arcangelo M, Rossi A. Deconstructing theory of mind in schizophrenia. Psychiatry Res. 201;190(1):32–36.
   PubMed Web of Science ®Google Scholar
• Fett AJ, Viechtbauer W, Dominguez M, Penn DL, van Os J, Krabbendam L. The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neurosci Biobehav Rev. 2011;35(3):573–588.
   PubMed Web of Science ®Google Scholar
• Kim HS, Shin NY, Jang JH, et al. Social cognition and neurocognition as predictors of conversion to psychosis in individuals at ultra-high risk. Schizophr Res. 2011;130(1–3):170–175.
   PubMed Web of Science ®Google Scholar
• Maher BA. Anomalous experience and delusional thinking: the logic of explanations. In: Oltmanns TF, Maher BA, editors. Delusional Beliefs. New York, NY, USA: Wiley; 1988.
   Google Scholar
• Garety PA, Freeman D. Cognitive approaches to delusions: a critical review of theories and evidence. Br J Clin Psychol. 1999;38 Pt 2:113–154.
   Google Scholar
• Bentall RP, Kinderman P, Kaney S. The self, attributional processes and abnormal beliefs: towards a model of persecutory delusions. Behav Res Ther. 1994;32(3):331–341.
   PubMed Web of Science ®Google Scholar
• McKay R, Langdon R, Coltheart M. Jumping to delusions? Paranoia, probabilistic reasoning, and need for closure. Cogn Neuropsychiatry. 2007;12(4):362–376.
   PubMedGoogle Scholar
• Bora E, Yucel M, Pantelis C. Theory of mind impairment in schizophrenia: meta-analysis. Schizophr Res. 2009;109(1–3):1–9.
   PubMed Web of Science ®Google Scholar
• Balzan RP, Delfabbro PH, Galletly CA, Woodward TS. Illusory correlations and control across the psychosis continuum: the contribution of hypersalient evidence-hypothesis matches. J Nerv Ment Dis. 2013;201(4):319–327.
   PubMed Web of Science ®Google Scholar
• Keefe RSE, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull. 1999;25(2):201–222.
   PubMed Web of Science ®Google Scholar
• Keefe RS, Bilder RM, Davis SM, et al; CATIE Investigators; Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry. 2007;64:633–647.
   PubMed Web of Science ®Google Scholar
• Szöke A, Trandafir A, Longitudinal studies of cognition in schizophrenia: meta-analysis. Br J Psychiatry. 2008;192(4):248–257.
   PubMed Web of Science ®Google Scholar
• Goldberg TE, Goldman RS, Burdick KE, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry. 2007;64(10):1115–1122.
   PubMed Web of Science ®Google Scholar
• Galletly CA, Clark R, McFarlane AC. Clozapine improves working memory updating in schizophrenia. Eur Neuropsychopharmacol. 2005;15(6):601–608.
   PubMed Web of Science ®Google Scholar
• Sood P, Idris NF, Cole S, Grayson B, Neill JC, Young AM. PD168077, a D(4) receptor agonist, reverses object recognition deficits in rats: potential role for D(4) receptor mechanisms in improving cognitive dysfunction in schizophrenia. J Psychopharmacol. 2011;25(6):792–800.
   PubMed Web of Science ®Google Scholar
• Corrigan MH, Gallen CC, Bonura ML, Merchant KM; Sonepiprazole Study Group. Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial. Biol Psychiatry. 2004;55(5):445–451.
   PubMed Web of Science ®Google Scholar
• Thakurathi N, Vincenzi B, Henderson DC. Assessing the prospect of donepezil in improving cognitive impairment in patients with schizophrenia. Expert Opin Investig Drugs. 2013;22(2):259–265.
   PubMed Web of Science ®Google Scholar
• Chouinard S, Stip E, Poulin J, et al. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits. Curr Med Res Opin. 2007;23(3):575–583.
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Khan A. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. Schizophr Res. 2011;125(2–3):267–277.
   PubMed Web of Science ®Google Scholar
• Ribeiz SR, Bassitt DP, Arrais JA, Avila R, Steffens DC, Bottino CM. Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature. CNS Drugs. 2010;24(4):303–317.
   PubMed Web of Science ®Google Scholar
• Singh J, Kour K, Jayaram MB. Acetylcholinesterase inhibitors for schizophrenia. Cochrane Database Syst Rev. 2012;1:CD007967.
   Web of Science ®Google Scholar
• de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005;76(2–3):135–157.
   PubMed Web of Science ®Google Scholar
• Chen XS, Li CB, Smith RC, Xiao ZP, Wang JJ. Differential sensory gating functions between smokers and non-smokers among drug-naive first episode schizophrenic patients. Psychiatry Res. 2011;188(3):327–333.
   PubMed Web of Science ®Google Scholar
• Freedman R, Coon H, Myles-Worsley M, et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci U S A. 1997;94(2):587–592.
   PubMed Web of Science ®Google Scholar
• Morisano D, Wing VC, Sacco KA, Arenovich T, George TP. Effects of tobacco smoking on neuropsychological function in schizophrenia in comparison to other psychiatric disorders and non-psychiatric controls. Am J Addict. 2013;22(1):46–53.
   PubMed Web of Science ®Google Scholar
• Young JW, Geyer MA. Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. Biochem Pharmacol. 2013;86(8):1122–1132.
   PubMed Web of Science ®Google Scholar
• Levin ED, Rezvani AH. Development of nicotinic drug therapy for cognitive disorders. Eur J Pharmacol. 2000;393(1–3):141–146.
   PubMed Web of Science ®Google Scholar
• Smith RC, Warner-Cohen J, Matute M, et al. Effects of nicotine nasal spray on cognitive function in schizophrenia. Neuropsychopharmacology. 2006;31(3):637–643.
   PubMed Web of Science ®Google Scholar
• Warburton DM, Rusted JM, Fowler J. A comparison of the attentional and consolidation hypotheses for the facilitation of memory by nicotine. Psychopharmacology (Berl). 1992;108(4):443–447.
   PubMed Web of Science ®Google Scholar
• Barr RS, Culhane MA, Jubelt LE, et al. The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology. 2008;33(3):480–490.
   PubMed Web of Science ®Google Scholar
• Freedman R, Olincy A, Buchanan RW, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry. 2008;165(8):1040–1047.
   PubMed Web of Science ®Google Scholar
• Wittkampf LC, Arends J, Timmerman L, Lancel M. A review of modafinil and armodafinil as add-on therapy in antipsychotic-treated patients with schizophrenia. Ther Adv Psychopharmacol. 2012;2(3):115–125.
   PubMedGoogle Scholar
• Wing VC, Wass CE, Bacher I, Rabin RA, George TP. Varenicline modulates spatial working memory deficits in smokers with schizophrenia. Schizophr Res. 2013;149(1–3):190–191.
   PubMed Web of Science ®Google Scholar
• Lohr JB, Liu L, Caligiuri MP, et al. Modafinil improves antipsychotic-induced parkinsonism but not excessive daytime sleepiness, psychiatric symptoms or cognition in schizophrenia and schizoaffective disorder: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2013;150(1):289–296.
   PubMed Web of Science ®Google Scholar
• Blasi G, Napolitano F, Ursini G, et al. Association of GSK-3β genetic variation with GSK-3β expression, prefrontal cortical thickness, prefrontal physiology, and schizophrenia. Am J Psychiatry. 2013;170(8):868–876.
   PubMed Web of Science ®Google Scholar
• King MK, Pardo M, Cheng Y, Downey K, Jope RS, Beurel E. Glycogen synthase kinase-3 inhibitors: rescuers of cognitive impairments. Pharmacol Ther. 2014;141(1):1–12.
   PubMed Web of Science ®Google Scholar
• Chan MH, Chiu PH, Lin CY, Chen HH. Inhibition of glycogen synthase kinase-3 attenuates psychotomimetic effects of ketamine. Schizophr Res. 2012;136(1–3):96–103.
   PubMed Web of Science ®Google Scholar
• de Bartolomeis A, Sarappa C, Magara S, Iasevoli F. Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia. Eur J Pharmacol. 2012;682(1–3):1–11.
   PubMed Web of Science ®Google Scholar
• Lin CY, Tsai GE, Lane HY. Assessing and treating cognitive impairments in schizophrenia: current and future. Curr Pharm Des. January 10, 2014. [Epub ahead of print.]
   Web of Science ®Google Scholar
• Galletly CA. Recent advances in treating cognitive impairment in schizophrenia. Psychopharmacology. 2009;202(1–3):259–273.
   PubMed Web of Science ®Google Scholar
• Dark F, Cairns A, Harris A. Cognitive remediation: the foundation of psychosocial treatment of schizophrenia. Aust N Z J Psychiatry. 2013;47(6):505–507.
   PubMed Web of Science ®Google Scholar
• Harvey K, Galletly C, Proeve M, Field C. The effects of verbalisation on cognitive performance in schizophrenia: a pilot study using tasks from the Delis Kaplan executive function system. Neuropsychol Rehabil. 2009;19(5):733–741.
   PubMed Web of Science ®Google Scholar
• McGurk SR, Mueser KT, Pascaris A. Cognitive training and supported employment for persons with severe mental illness: one-year results from a randomized controlled trial. Schizophr Bull. 2005;31(4):898–909.
   PubMed Web of Science ®Google Scholar
• Royer A, Grosselin A, Bellot C, et al. Is there any impact of cognitive remediation on an ecological test in schizophrenia? Cogn Neuropsychiatry. 2012;17(1):19–35.
   PubMed Web of Science ®Google Scholar
• Bowie CR, McGurk SR, Mausbach B, Patterson TL, Harvey PD. Combined cognitive remediation and functional skills training for schizophrenia: effects on cognition, functional competence, and real-world behavior. Am J Psychiatry. 2012;169(7):710–718.
   PubMed Web of Science ®Google Scholar
• McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT. A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry. 2007;164(12):1791–1802.
   PubMed Web of Science ®Google Scholar
• Wykes T, Reeder C, Landau S, et al. Cognitive remediation therapy in schizophrenia: randomised control trial. Br J Psychiatry. 2007;190(5):421–427.
   PubMedGoogle Scholar
• Wykes T. Cognitive remediation therapy needs funding. Nature. 2010;468(7321):165–166.
   PubMed Web of Science ®Google Scholar
• Velligan DI, Diamond PM, Maples NJ, et al. Comparing the efficacy of interventions that use environmental supports to improve outcomes in patients with schizophrenia. Schizophr Res. 2008;102(1–3):312–319.
   PubMed Web of Science ®Google Scholar
• Statucka M, Walder DJ. Efficacy of social cognition remediation programs targeting facial affect recognition deficits in schizophrenia: a review and consideration of high-risk samples and sex differences. Psychiatry Res. 2013;206(2–3):125–139.
   PubMed Web of Science ®Google Scholar
• Sacks S, Fisher M, Garrett C, et al. Combining computerized social cognitive training with neuroplasticity-based auditory training in schizophrenia. Clin Schizophr Relat Psychoses. 2013;7(2):78A–86A.
   PubMedGoogle Scholar
• Hogarty GE, Flesher S, Ulrich R, et al. Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior. Arch Gen Psychiatry. 2004;61(9):866–876.
   PubMed Web of Science ®Google Scholar
• Moritz S, Woodward TS. Metacognitive training in schizophrenia: from basic research to knowledge translation and intervention. Curr Opin Psychiatry. 2007;20(6):619–625.
   PubMed Web of Science ®Google Scholar
• Aghotor J, Pfueller U, Moritz S, Weisbrod M, Roesch-Ely D. Metacognitive training for patients with schizophrenia (MCT):Feasibility and preliminary evidence for its efficacy. J Behav Ther Exp Psychiatry. 2010;41(3):207–211.
   PubMed Web of Science ®Google Scholar
• Rajji TK, Rogasch NC, Daskalakis ZJ, Fitzgerald PB. Neuroplasticity-based brain stimulation interventions in the study and treatment of schizophrenia: a review. Can J Psychiatry. 2013;58(2):93–98.
   PubMed Web of Science ®Google Scholar
• Voineskos D, Daskalakis ZJ. A primer on the treatment of schizophrenia through repetitive transcranial magnetic stimulation. Expert Rev Neurother. 2013;13(10):1079–1082.
   PubMed Web of Science ®Google Scholar
• Aleman A, Sommer IE, Kahn RS. Efficacy of slow repetitive transcranial magnetic stimulation in the treatment of resistant auditory hallucinations in schizophrenia: a meta-analysis. J Clin Psychiatry. 2007;68(3):416–421.
   PubMed Web of Science ®Google Scholar
• Slotema CW, Blom JD, Hoek HW, et al. Should we expand the toolbox of psychiatric treatment methods to include repetitive transcranial magnetic stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. J Clin Pscyhiatry. 2010;71(7):873–884.
   PubMed Web of Science ®Google Scholar
• Sachdev P, Loo C, Mitchell P, et al. Transcranial magnetic stimulation for the deficit syndrome of schizophrenia: a pilot investigation. Psychiatry Clin Neurosci. 2005;59(3):354–357.
   PubMed Web of Science ®Google Scholar
• Jin Y, Potkin SG, Kemp AS, et al. Alpha EEG guided TMS in schizophrenia. Brain Stimul. 2012;5(4):560–568.
   PubMed Web of Science ®Google Scholar
• Prikryl R, Kasparek T, Skotakova S, et al. Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double-blind, randomized controlled study. Schizophr Res. 2007;95(1–3):151–157.
   PubMed Web of Science ®Google Scholar
• Levkovitz Y, Rabany L, Harel EV, Zangen A. Deep transcranial magnetic stimulation add-on for treatment of negative symptoms and cognitive deficits of schizophrenia: a feasibility study. Int J Neuropsychopharmacol. 2011;14(7):991–996.
   PubMed Web of Science ®Google Scholar
• Ditye T, Jacobson L, Walsh V, Lavidor M. Modulating behavioral inhibition by tDCS combined with cognitive training. Exp Brain Res. 2012;219(3):363–368.
   PubMed Web of Science ®Google Scholar
• Wing VC, Bacher I, Wu BS, Daskalakis ZJ, George TP. High frequency repetitive transcranial magnetic stimulation reduces tobacco craving in schizophrenia. Schizophr Res. 2012;139(1–3):264–266.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. NICE clinical guidelines. Available at: http://guidance.nice.org.uk/CG/Published. Accessed March 4, 2014.
   Google Scholar